Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivoryon Therapeutics N.V. is set to release its half-year 2024 financial results on September 12, 2024, accompanied by a public webcast and conference call. Additionally, the company will host a virtual event focusing on Kidney Disease with key opinion leaders on September 30, 2024, with details to be announced on their website. As a clinical stage biotechnology firm, Vivoryon is dedicated to developing small molecule-based medicines for severe diseases, including Alzheimer’s, kidney disorders, and cancer.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.